Alterity Operating Margin from 2010 to 2024
| ATHE Stock | USD 1.07 0.02 1.90% |
Check Alterity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alterity Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 2.9 K, Other Operating Expenses of 10 M or Total Operating Expenses of 10 M, as well as many indicators such as Price To Sales Ratio of 4.31, Dividend Yield of 0.0 or PTB Ratio of 1.39. Alterity financial statements analysis is a perfect complement when working with Alterity Therapeutics Valuation or Volatility modules.
Alterity | Operating Margin |
Latest Alterity Therapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Alterity Therapeutics over the last few years. It is Alterity Therapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alterity Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (6.13) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Alterity Operating Margin Regression Statistics
| Arithmetic Mean | (31.32) | |
| Coefficient Of Variation | (104.87) | |
| Mean Deviation | 25.86 | |
| Median | (28.49) | |
| Standard Deviation | 32.84 | |
| Sample Variance | 1,079 | |
| Range | 114 | |
| R-Value | 0.35 | |
| Mean Square Error | 1,020 | |
| R-Squared | 0.12 | |
| Significance | 0.20 | |
| Slope | 2.56 | |
| Total Sum of Squares | 15,101 |
Alterity Operating Margin History
About Alterity Therapeutics Financial Statements
Alterity Therapeutics stakeholders use historical fundamental indicators, such as Alterity Therapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Although Alterity Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Alterity Therapeutics' assets and liabilities are reflected in the revenues and expenses on Alterity Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Alterity Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Alterity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out the analysis of Alterity Therapeutics Correlation against competitors. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.88) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.